BioSpace News Archive

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that Steve Doares, Ph.D., joins Cellectis from Biogen as Senior Vice President of US Manufacturing Manufacturing and Site Head of Raleigh manufacturing plant in NC.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. Eastern Time

Option Care Health, Inc. announced the pricing of an underwritten offering of 18,000,000 shares of its common stock, which includes 10,000,000 shares offered by the Company and 8,000,000 shares offered by an affiliate of Madison Dearborn Partners, at a price to the public of $12.50 per share. The Selling Stockholder has granted the underwriters a 30-day option to purchase up to 2,700,000 additional shares of common stock.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic:.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381 Class A common shares at a public offering price of $21.00 per share, before underwriting discounts and commissions.

[21-July-2020] STATESVILLE, N.C. , July 21, 2020 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2020. Fiscal Year 2020 Fourth Quarter Results: Sales during t

GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on Tuesday, August 4, 2020.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

Berkeley Lights, Inc. announced the closing of its initial public offering of 9,315,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,215,000 shares of common stock, at a public offering price of $22.00 per share.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it is rescheduling the date of the Company’s Special Meeting of Stockholders (the “Special Meeting”) previously scheduled for Friday, June 26, 2020, to Friday, August 28, 2020, at 11:00 a.m., Eastern Time.